SecBot SecBot
6-K ·Filed May 18, 2026

DRTSW

Alpha Tau Medical Ltd.
NEUTRAL
Impact 5/10
Horizonmonths Processed6mo ago SEC0001213900-26-058424
Notable filing: 6-K
Actionable Insight • Neutral

The clinical catalysts (REGAIN data, ReSTART enrollment completion, PMDA approval) are positive but pre-revenue biotech with widening losses and non-cash warrant volatility. Key binary events: ReSTART top-line data around end-2026 and IMPACT pancreatic enrollment completion in Q3 2026. Monitor cash burn trajectory and any secondary offering risk given $80.2M cash position.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.02
T+0 close · May 18, 2026 · via day close
Latest settled
+281.37%
T+60 · $3.89
Vs SPY
+275.08%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 19 $1.02entry
  2. T+1 · 6mo ago 0.00%α −1.04% · $1.02
  3. T+5 · 6mo ago +150.98%α +148.73% · $2.56
  4. T+20 · 5mo ago +93.63%α +92.64% · $1.98
  5. T+60 · 3mo ago +281.37%α +275.08% · $3.89
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alpha Tau reported Q1 2026 financial results with net loss widening to $22.9M ($0.26/share) from $8.7M ($0.12/share) YoY, driven by a $9.6M non-cash remeasurement of warrants liability and increased R&D spend. Operationally, the company highlighted strong interim REGAIN glioblastoma data (67% complete response rate), completion of enrollment in the pivotal ReSTART cSCC trial (88 patients), and PMDA approval in Japan. Cash of $80.2M provides runway into 2027.

Key Facts

  • Net loss of $22.9M in Q1 2026 vs $8.7M in Q1 2025; EPS -$0.26 vs -$0.12
  • Operating loss widened to $13.3M from $9.3M YoY, driven by R&D spend up to $11.0M from $7.2M
  • Financial expense of $9.6M vs income of $0.7M YoY due to warrants liability remeasurement
  • Cash, equivalents, short-term and restricted deposits of $80.2M at March 31, 2026 vs $76.9M at Dec 31, 2025
  • REGAIN glioblastoma trial: 100% local disease control, 67% complete response rate in first 3 patients
  • ReSTART pivotal cSCC trial completed enrollment with 88 patients; first module of PMA submitted Jan 2026
  • PMDA marketing approval received in Japan for head and neck cancer; post-market surveillance study ongoing
  • Shares outstanding increased to 90.2M from 88.0M at Dec 31, 2025
  • Warrants liability increased to $15.7M from $5.4M at Dec 31, 2025

Financial Impact

Net loss increased by $14.2M YoY; operating cash burn ~$13.3M/quarter; cash runway ~6 quarters at current burn rate

net lossepsoperating expensescashwarrants liability

Risk Factors

  • Pre-revenue company with no approved products in the US; commercialization dependent on FDA PMA approval
  • Widening net loss and operating loss; cash burn rate may require additional financing within 12-18 months
  • Warrants liability creates significant non-cash earnings volatility ($15.7M at Q1 end)
  • Clinical trial risks: REGAIN and IMPACT data are early-stage; ReSTART pivotal data may not meet endpoints
  • Share count increased 2.5% since year-end, potential dilution from warrant exercises or future offerings

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-058424
Document: ea0290584-6k_alpha.htm0001213900-26-058424
Document: 0001213900-26-058424-index-headers.html0001213900-26-058424
Document: 0001213900-26-058424-index.html0001213900-26-058424
Document: 0001213900-26-058424.txt0001213900-26-058424

Track record

14 reports on DRTSW

Performance horizon

9 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +292.16% at T+60 after the Jun 3, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Jun 3, 202623w ago 6-K Bullish 7/10 Entry $1.02 to $4.00 ▲ +292.16% +289.66% vs SPY
  2. Jun 1, 202624w ago 6-K Bullish 7/10 Entry $1.02 to $3.89 ▲ +281.37% +280.14% vs SPY
  3. May 18, 202626w ago 6-K Neutral 5/10 Viewing Entry $1.02 to $3.89 ▲ +281.37% +275.08% vs SPY
  4. May 11, 202627w ago 6-K Bullish 7/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
  5. May 11, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
  6. May 8, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
  7. May 8, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
  8. May 7, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.58 ▲ +152.94% +149.11% vs SPY
  9. May 5, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.70 ▲ +164.71% +161.97% vs SPY
  10. May 4, 202628w ago 6-K Bullish 7/10 Entry $1.02 to $2.29 ▲ +124.51% +122.65% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 7h 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 18, 2026